Australian pharmaceutical
research received a boost yesterday
with the announcement of a
major deal between the Australian
biotech firm and Merck, to finance
the development of small molecule
candidates for pain therapy.
The deal, worth up to $172m,
gives Merck the option to
exclusively license a compound
from Bionomics for development
and commercialisation.
Bionomics will use its ionX drug
discovery platform and MultiCore
chemistry to identify potential
candidate molecules.
The initial period of the research
program will be two years.
Investigations will cover both
chronic and neuropathic pain, with
the global pain treatment market
estimated to be worth around
US$19 billion annually.The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 13 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 13
THE stark health inequalities between Australians living in regional and metro areas have been highlighted in a new report from The Royal Flying Doctor Service (RFDS).
AN “AI explosion” is sweeping Australia’s healthcare sector, signalling the arrival of an “extraordinary era of medicine”, according to a new report from CSIRO.
THE Australian and New Zealand College of Advanced Pharmacy (ANZCAP) has celebrated the 1,000th pharmacist to complete its pharmacy recognition program (PD 24 Nov 2023).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.